[1] Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet (London, England). 2011;378(9786):182-197. doi: 10.1016/s0140-6736(11)60207-9.
[2] Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ (Clinical research ed). 2020;369:m997. doi: 10.1136/bmj.m997.
[3] Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nature reviews Gastroenterology & hepatology. 2017;14(1):32-42. doi: 10.1038/nrgastro.2016.147.
[4] Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiological reviews. 2018;98(4):2133-2223. doi: 10.1152/physrev.00063.2017.
[5] Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59(2):713-723. doi: 10.1002/hep.26672.
[6] Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019;40(5):1367-1393. doi: 10.1210/er.2019-00034.
[7] Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nature reviews Endocrinology. 2017;13(9):509-520. doi: 10.1038/nrendo.2017.56.
[8] Jung TW, Yoo HJ, Choi KM. Implication of hepatokines in metabolic disorders and cardiovascular diseases. BBA clinical. 2016;5:108-113. doi: 10.1016/j.bbacli.2016.03.002.
[9] Huang RL, Li CH, Du YF, Cheng KP, Lin CH, Hu CY, et al. Discovery of a role of the novel hepatokine, hepassocin, in obesity. BioFactors (Oxford, England). 2020;46(1):100-105. doi: 10.1002/biof.1574.
[10] Ennequin G, Sirvent P, Whitham M. Role of exercise-induced hepatokines in metabolic disorders. Am J Physiol Endocrinol Metab. 2019;317(1):E11-e24. doi: 10.1152/ajpendo.00433.2018.
[11] Misu H. Identification of hepatokines involved in pathology of type 2 diabetes and obesity. Endocr J. 2019;66(8):659-662. doi: 10.1507/endocrj.EJ19-0255.
[12] Kaur P, Rizk NM, Ibrahim S, Younes N, Uppal A, Dennis K, et al. iTRAQ-based quantitative protein expression profiling and MRM verification of markers in type 2 diabetes. Journal of proteome research. 2012;11(11):5527-5539. doi: 10.1021/pr300798z.
[13] Yang J, Zhou W, Zhu J, Wu Y, Xu L, Wang Y, et al. Circulating ectodysplasin A is a potential biomarker for nonalcoholic fatty liver disease. Clin Chim Acta. 2019;499:134-141. doi: 10.1016/j.cca.2019.09.009.
[14] Awazawa M, Gabel P, Tsaousidou E, Nolte H, Krüger M, Schmitz J, et al. A microRNA screen reveals that elevated hepatic ectodysplasin A expression contributes to obesity-induced insulin resistance in skeletal muscle. Nat Med. 2017;23(12):1466-1473. doi: 10.1038/nm.4420.
[15] Ezer S, Bayés M, Elomaa O, Schlessinger D, Kere J. Ectodysplasin is a collagenous trimeric type II membrane protein with a tumor necrosis factor-like domain and co-localizes with cytoskeletal structures at lateral and apical surfaces of cells. Human molecular genetics. 1999;8(11):2079-2086. doi: 10.1093/hmg/8.11.2079.
[16] Chen Y, Molloy SS, Thomas L, Gambee J, Bächinger HP, Ferguson B, et al. Mutations within a furin consensus sequence block proteolytic release of ectodysplasin-A and cause X-linked hypohidrotic ectodermal dysplasia. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(13):7218-7223. doi: 10.1073/pnas.131076098.
[17] Nikopensius T, Annilo T, Jagomägi T, Gilissen C, Kals M, Krjutškov K, et al. Non-syndromic tooth agenesis associated with a nonsense mutation in ectodysplasin-A (EDA). Journal of dental research. 2013;92(6):507-511. doi: 10.1177/0022034513487210.
[18] Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34 Suppl 1(Suppl 1):S62-69. doi: 10.2337/dc11-S062.
[19] Hoffman RP. Indices of insulin action calculated from fasting glucose and insulin reflect hepatic, not peripheral, insulin sensitivity in African-American and Caucasian adolescents. Pediatric diabetes. 2008;9(3 Pt 2):57-61. doi: 10.1111/j.1399-5448.2007.00350.x.
[20] Zaret KS. Genetic programming of liver and pancreas progenitors: lessons for stem-cell differentiation. Nature reviews Genetics. 2008;9(5):329-340. doi: 10.1038/nrg2318.
[21] Yang L, Li S, Hatch H, Ahrens K, Cornelius JG, Petersen BE, et al. In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(12):8078-8083. doi: 10.1073/pnas.122210699.
[22] Fairhall EA, Leitch AC, Lakey AF, Probert PME, Richardson G, De Santis C, et al. Glucocorticoid-induced pancreatic-hepatic trans-differentiation in a human cell line in vitro. Differentiation; research in biological diversity. 2018;102:10-18. doi: 10.1016/j.diff.2018.05.003.
[23] Iroz A, Couty JP, Postic C. Hepatokines: unlocking the multi-organ network in metabolic diseases. Diabetologia. 2015;58(8):1699-1703. doi: 10.1007/s00125-015-3634-4.
[24] Taskinen MR, Borén J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239(2):483-495. doi: 10.1016/j.atherosclerosis.2015.01.039.
[25] Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46(6):733-749. doi: 10.1007/s00125-003-1111-y.
[26] Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886-899. doi: 10.1007/s00125-015-3525-8.
[27] Glueck CJ, Khan NA, Umar M, Uppal MS, Ahmed W, Morrison JA, et al. Insulin resistance and triglycerides. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2009;57(8):874-881. doi: 10.2310/JIM.0b013e3181bca9d2.
[28] Titchenell PM, Lazar MA, Birnbaum MJ. Unraveling the Regulation of Hepatic Metabolism by Insulin. Trends in endocrinology and metabolism: TEM. 2017;28(7):497-505. doi: 10.1016/j.tem.2017.03.003.
[29] Pasquali R, Casanueva F, Haluzik M, van Hulsteijn L, Ledoux S, Monteiro MP, et al. European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity. European journal of endocrinology. 2020;182(1):G1-g32. doi: 10.1530/eje-19-0893.
[30] Fathzadeh M, Li J, Rao A, Cook N, Chennamsetty I, Seldin M, et al. FAM13A affects body fat distribution and adipocyte function. Nature communications. 2020;11(1):1465. doi: 10.1038/s41467-020-15291-z.